Abstract:Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) have revolutionized the management of hormone receptor-positive (HR +) breast cancer. However, resistance to CDK4/6i remains an unavoidable challenge, with limited evidence to guide the choice of subsequent treatments. Continuation of CDK4/6 inhibition raises as a compelling treatment option and is currently an active area of research. This approach encompasses multifaceted strategies regarding CDK4/6i sequence (same or switched agent), endocrine therapy (ET) partner and potential combination with a third drug. Continuing CDK4/6 inhibition while targeting ET resistance in tumours still dependent on ER activity (i.e., ESR1 mutation) through a ctDNA-guided approach has the potential of becoming practice-changing, pending the results of ongoing phase III studies. Conversely, the efficacy of this strategy in cases of radiological progression in a biomarker-unselected population appears to be rather unsatisfactory. While some benefit, albeit modest, has been observed from switching to a different CDK4/6i after progression (e.g. ribociclib after palbociclib in the MAINTAIN trial and abemaciclib after both palbociclib and ribociclib in the postMONARCH trial), the current evidence (mainly with palbociclib) clearly argues against maintaining the same CDK4/6i. Biomarker analyses to optimally identify patients suitable for this approach yielded inconsistent findings that do not apply to daily clinical decision making. Attractive preliminary efficacy has recently emerged from combining a third agent (immunotherapy, AKT/ PIK3CA/mTOR inhibitor, new ET agents, CDK2 inhibitors) to CDK4/6i and ET, but further validation in larger ongoing trials is required to also determine the optimal timing for incorporating these agents into the therapeutic timeline. To date, CDK4/6i after CDK4/6i progression is far from being a standard of care. However, selected patients with indolent disease, prolonged exposure to previous CDK4/6i treatment (especially palbociclib) and without actionable molecular alterations, may be suitable for suchmaintenance strategy beyond progression. In this challenging and rapidly evolving treatment landscape, ongoing studies can refine the optimal approach and identify clinical and molecular factors to select the best treatment for the right patient.

Recommendations for cyclin‐dependent kinase 4/6 inhibitor treatments in the context of co‐morbidity and drug interactions (Review)

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

Cyclin-dependent Kinase 4 and 6 Inhibitors at the Crossroads: the Combinational Therapeutic Strategies in Breast Cancer—a Narrative Review

An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients

The Use of Cyclin-Dependent Tyrosine Kinase 4/6 (CDK4/6) Inhibitors in Breast Cancer

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

A Narrative Review about CDK4/6 Inhibitors in the Setting of Drug Resistance: Updates on Biomarkers and Therapeutic Strategies in Breast Cancer

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer

Combination Cyclin-Dependent Kinase 4/6 Inhibitors and Endocrine Therapy Versus Endocrine Monotherapy for Hormonal Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Systematic Review and Meta-Analysis

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Overall Survival and Progression-Free Survival with Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer: an Updated Meta-Analysis of Randomized Controlled Trials

Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers

Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer

Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR+/HER2– advanced/metastatic breast cancer

Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer